| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Neutrophil Gelatinase-Associated Lipocalin, Lipocalin-2, Siderocalin
MessagePerformed in Chemistry at BDMC
Test Code
NGALU
Alias/See Also
NGAL, Urine
CPT Codes
83520
Preferred Specimen
Urine, yellow top tube (urine tube)
Minimum Volume
200 µL
Other Acceptable Specimens
None
Instructions
Centrifuge samples before performing the assay. Analyze as soon as possible after collection.
Transport Temperature
Refrigerated
Specimen Stability
Ambient 24 hours
Refrigerated 3 days
Frozen 3 days
Refrigerated 3 days
Frozen 3 days
Methodology
EIA
FDA Status
Lab Modified
Setup Schedule
Continously; Sunday through Saturday
Report Available
Same day
Reference Range
Unit of Measure: ng/mL
Male/Female 0 - 150 years
<50
Interpretive Data
The following will be added to each result: Suggested Acute Kidney Injury Risk Cut-Offs
•Low: < 50 ng/mL
•Equivocal: 50-149 ng/mL
•Moderate: 150-300 ng/mL
•High Risk: > 300 ng/mL
Low or equivocal risk does not exclude subsequent development of AKI. Perform repeat testing if clinically indicated.
Male/Female 0 - 150 years
<50
Interpretive Data
The following will be added to each result: Suggested Acute Kidney Injury Risk Cut-Offs
•Low: < 50 ng/mL
•Equivocal: 50-149 ng/mL
•Moderate: 150-300 ng/mL
•High Risk: > 300 ng/mL
Low or equivocal risk does not exclude subsequent development of AKI. Perform repeat testing if clinically indicated.
Clinical Significance
Acute kidney injury (AKI), previously known as acute renal failure, represents a medical emergency and encompasses a wide range of injury to the kidneys. Acute kidney injury is a rapid deterioration of renal function, resulting in an inability to maintain fluid, electrolyte and acid-base balance. AKI increase morbidity and mortality and due to the severity of acute kidney injury the healthcare costs are significant. As a result of this increased efforts into identifying new acute kidney injury biomarkers can be seen, as biomarkers addressing the need for earlier diagnosis of AKI would ultimately save lives, raise quality of life for patients worldwide and save costs for the healthcare system. NGAL (neutrophil gelatinase-associated lipocalin, lipocalin-2, siderocalin) is a novel biomarker for diagnosing acute kidney injury (AKI). Under normal conditions NGAL levels are low in urine and plasma but rise sharply from basal levels in response to kidney injury to reach diagnostic levels within a very short time - as much as 24 hours or more before any significant rise in serum creatinine. NGAL is a small protein expressed in neutrophils and certain epithelia, including the renal tubules. Renal expression of NGAL is dramatically increased in kidney injury from a variety of causes, and NGAL is released into both urine and plasma. NGAL levels rise within 2 hours of the insult, making NGAL an early and sensitive biomarker of kidney injury.
Performing Laboratory
Banner Desert Medical Center - Lab
